These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 27965826)
1. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Snee MP; McParland L; Collinson F; Lowe CM; Striha A; Baldwin DR; Naidu B; Sebag-Montefiore D; Gregory WM; Bestall J; Hewison J; Hinsley S; Franks K Pilot Feasibility Stud; 2016; 2():5. PubMed ID: 27965826 [TBL] [Abstract][Full Text] [Related]
2. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. Franks KN; McParland L; Webster J; Baldwin DR; Sebag-Montefiore D; Evison M; Booton R; Faivre-Finn C; Naidu B; Ferguson J; Peedell C; Callister MEJ; Kennedy M; Hewison J; Bestall J; Gregory WM; Hall P; Collinson F; Olivier C; Naylor R; Bell S; Allen P; Sloss A; Snee M Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 32616595 [TBL] [Abstract][Full Text] [Related]
3. Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Snee MP; McParland L; Collinson F; Lowe CM; Striha A; Baldwin DR; Naidu B; Sebag-Montefiore D; Gregory WM; Bestall J; Hewison J; Hinsley S; Franks KN Pilot Feasibility Stud; 2016; 2():55. PubMed ID: 27976752 [TBL] [Abstract][Full Text] [Related]
4. Patient reported outcomes following video assisted thoracoscopic (VATS) resection or stereotactic ablative body radiotherapy (SABR) for treatment of non-small cell lung cancer: protocol for an observational pilot study (LiLAC). Pompili C; Franks KN; Brunelli A; Hussain YS; Holch P; Callister ME; Robson JM; Papagiannopoulos K; Velikova G J Thorac Dis; 2017 Aug; 9(8):2703-2713. PubMed ID: 28932579 [TBL] [Abstract][Full Text] [Related]
5. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B; Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291 [TBL] [Abstract][Full Text] [Related]
6. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. Conibear J; Chia B; Ngai Y; Bates AT; Counsell N; Patel R; Eaton D; Faivre-Finn C; Fenwick J; Forster M; Hanna GG; Harden S; Mayles P; Moinuddin S; Landau D BMJ Open; 2018 Apr; 8(4):e020690. PubMed ID: 29666135 [TBL] [Abstract][Full Text] [Related]
7. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. Davidson B; Gurusamy K; Corrigan N; Croft J; Ruddock S; Pullan A; Brown J; Twiddy M; Birtwistle J; Morris S; Woodward N; Bandula S; Hochhauser D; Prasad R; Olde Damink S; Coolson M; Laarhoven KV; de Wilt JH Health Technol Assess; 2020 Apr; 24(21):1-38. PubMed ID: 32370822 [TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805 [TBL] [Abstract][Full Text] [Related]
9. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer? Mahmood S; Bilal H; Faivre-Finn C; Shah R Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381 [TBL] [Abstract][Full Text] [Related]
10. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789 [TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer. Phillips I; Sandhu S; Lüchtenborg M; Harden S Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806 [TBL] [Abstract][Full Text] [Related]
14. [Current Status of Stereotactic Ablative Radiotherapy (SABR) for Early-stage Non-small Cell Lung Cancer]. Shi A; Zhu G Zhongguo Fei Ai Za Zhi; 2016 Jun; 19(6):389-93. PubMed ID: 27335303 [TBL] [Abstract][Full Text] [Related]
15. Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. Rusthoven CG; Kavanagh BD; Karam SD Ann Transl Med; 2015 Jul; 3(11):149. PubMed ID: 26244136 [TBL] [Abstract][Full Text] [Related]
16. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? Bilal H; Mahmood S; Rajashanker B; Shah R Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864 [TBL] [Abstract][Full Text] [Related]